Translated material
An analogue of the drug for HIV prevention will increase its availability in 120 countries
The American company Gilead Sciences has concluded a deal with six pharmaceutical companies for the production of analogues of its Lenakapavir drug used to prevent HIV infection. They will be available at a reduced price in 120 countries, writes The Guardian.
Lenacapavir is a drug for HIV prevention, which is produced in the form of injections and tablets . The injection drug is administered intramuscularly twice a year. He showed his one hundred percent effectiveness in one of the clinical trials - it was reported that none of the more than two thousand women and girls from South Africa and Uganda, who injected the drug, did not become infected with HIV. At the same time, the sponsor of this study was the manufacturing company itself.
Over the years with HIV, my life has become only better, I am not embarrassed to talk about my diagnosis, and he did not stop me from emigrating society 11 minutes of reading
The problem of the drug lies in its cost - $ 42,250 for the annual rate. Journalists note that on Gilead Sciences put pressure with the demand to reduce the price and make it affordable all over the world. Some researchers even considered that it can be profitably produced for only $ 40.
Gilead Sciences announced that it has signed an agreement for the production and sale of generics with six pharmaceutical companies in the USA, Egypt, Pakistan and India. According to the terms of the agreement, the analogues of the drug will be available at a reduced price in 120 states with low and medium income.
However, international organizations drew attention to the fact that the countries of Latin America did not include in this list.
“GILEAD has ignored the country with the income above average, where the number of new cases of infection is the greatest-almost all of Latin America was excluded from this list,” said the representative of the non-profit organization of PEOPLE' MEDICINES ALLIANCE, Dr. Mokhga Kamal-Yanga.
“Granny confused addresses, and instead of the AIDS of the center we came to the pizzeria” teenagers with HIV tell their stories society 11 minutes of reading
UNAIDS Executive Director Winnie Byanima noted: if the drug becomes available to everyone who needs it, then this will help “change the situation” in the fight against HIV.
Gilead Sciences said that by the end of 2024 it would begin to apply for a global permission to use Lenacapavir as a means of HIV prevention.
In 2023, 1.3 million new cases of HIV infection were registered in the world. According to The New York Times, the need for more effective HIV prevention methods has become extremely relevant, because existing oral preparations for HIV prevention could not reduce the number of new cases of infection among the most vulnerable groups.
In order not to miss the main materials of the "cold", subscribe to our social networks!
